Geras Solutions

What Geras Solutions does

Geras Solutions AB is a Swedish digital health company founded in 2015 and headquartered in Stockholm, specializing in CE-marked digital cognitive assessment and decision-support tools for dementia evaluation. The company's platform enables tablet-based self-administration of cognitive screening tests (digital versions of MoCA, MMSE, and clock-drawing tests) combined with structured digital anamnesis and the CIMP-QUEST relative symptom questionnaire. Results are automatically analyzed with AI-assisted interpretation and presented in a clinical interface that includes cut-off scores for different levels of cognitive impairment. The platform is CE-marked as a Class I medical device under MDD and Class IIa under MDR, with ISO 13485 quality certification.

The company serves three primary customer segments: Swedish public healthcare providers (primary care centers and specialist memory clinics), four regional healthcare authorities (Värmland, Halland, Västra Götaland, Sörmland), and pharmaceutical/academic research institutions conducting cognitive clinical trials. Its GTM motion is enterprise field sales targeting healthcare institutions, supported by clinical validation from Karolinska University Hospital and endorsements from Svenskt Demenscentrum. The Minnesmottagningen.se patient portal provides direct access to self-administered cognitive testing and FINGER-study-based brain health risk-reduction content.

Geras Solutions generates revenue through B2B subscription licensing of its medical device platform to healthcare providers, with quote-based annual pricing. The company has raised approximately $1.5M in a single funding round from Add Health Media in 2019 and operates with a team of 11-50 employees. It is registered as a healthcare provider with the Swedish IVO (Inspektionen för vård och omsorg) and was featured in the Alzheimer's Disease International 'From Plan to Impact' annual report in 2024.

Name

Geras Solutions

Legal name

Geras Solutions AB

Website

https://gerassolutions.com

Company type

Private

Founded year

2015

Operating status

Operating

Headcount range

11–50 employees

Short description

Geras Solutions AB is a Stockholm-based digital health company providing CE-marked, AI-assisted cognitive assessment and decision-support tools for dementia diagnosis, serving Swedish healthcare providers, regional authorities, and pharmaceutical research institutions through a tablet-based platform.

Ownership category

akta.pro rank

Product category

Digital Health - Cognitive Assessment & Dementia Diagnostics

NAICS

Services for the Elderly and Persons with Disabilities (62412), Computer Systems Design Services (541512), Other Computer Related Services (541519)

SIC

Services-Prepackaged Software (7372), Services-Computer Integrated Systems Design (7373)

akta.pro primary industry

Memory Care Care Management & Navigation (Dementia Care Coordination) (HLADACAJ)

akta.pro secondary industries

Chronic Care & Complex Care Management (HSABAIAD), eCOA/ePRO/eDiary & Patient-Facing Data Collection (HLACAOAB), Geriatric, Frailty & Fall-Prevention Remote Monitoring (HLALAFAI)

Keywords

• Digital cognitive assessment
• Dementia diagnostic platform
• Medical device software
• Clinical decision support
• Healthcare provider licensing

Headquarters

HQ city

Stockholm

HQ country

Sweden

HQ region

Europe

Offices1 record

Markets served

GTM type

B2B

Offering type

Software

Cost components

Personnel, Technology or R&D, Operations, Marketing or Sales, Others

Revenue model

1. Healthcare Provider Licensing: B2B licensing of the CE-marked medical device (Class I under MDD, Class IIa under MDR) to healthcare providers including primary care centers and specialist memory clinics. Revenue likely generated through subscription or per-assessment licensing to healthcare institutions.

Pricing tiers

Go-to-market motion1 record

Distribution channels2 records

Marketing channels4 records

Core offering

Geras Solutions provides a CE-marked digital cognitive assessment and clinical decision support platform (Geras Suite) that enables tablet-based self-administered cognitive screening tests, automated medical history collection (anamnesis), relative-input symptom questionnaires, and AI-driven result compilation for dementia diagnostics in primary care and specialist memory clinic settings. The offering is delivered to Swedish healthcare providers via subscription licensing, complemented by the Minnesmottagningen.se patient portal and a separate platform for pharmaceutical and academic research.

Product overview

Geras Solutions provides a unified digital health platform for cognitive assessment and dementia diagnosis. The core offering is the Geras Solutions (Geras Suite) platform — a CE-marked medical device combining cognitive screening tests, automated anamnesis, and relative symptom inventories into a single workflow. This is offered alongside Minnesmottagningen, a patient-facing memory clinic service accessible via app. The Geras Clinic interface provides the clinical decision-support layer for healthcare providers. For pharmaceutical and academic research, a dedicated platform offers validated cognitive testing, longitudinal study management, and structured data handling. All components share a common technology foundation for tablet/phone-based testing and AI-powered result analysis.

Differentiator

Problem solved

Functional benefit

Brands

• Minnesmottagningen: Patient-facing portal for cognitive assessment and memory clinic services
• Geras Suite
• Geras Clinic

Products and services

• Geras Solutions (Geras Suite) CE-marked digital diagnostic and decision support platform for standardized cognitive and dementia assessment at primary care and specialist clinics. Enables tablet-based self-administered cognitive testing, automated anamnesis, relative symptom inventories, and direct result compilation for clinical evaluation. Sold to healthcare institutions on an annual subscription.
• Minnesmottagningen (Memory Clinic Patient Portal) Patient-facing portal and app providing comprehensive cognitive assessment services to relieve primary care centers across Sweden. Includes risk reduction tools based on FINGER study methodology for brain health with guidance on diet, exercise, social interaction, and cognitive training. Accessible via healthcare referral.
• Geras Solutions for Pharma & Akademi Dedicated platform offering validated digital cognitive testing for pharmaceutical clinical trials and academic research. Enables clinical trial cognitive endpoints, participant recruitment with defined criteria, longitudinal study follow-up, structured data collection, and perisurgical cognitive assessment, with results analyzed via AI and presented in a separate researcher interface.

Quantifiable outcome

• Higher sensitivity and specificity than established methods (clinical study at Karolinska University Hospital)
• +1 more outcomes

Named customers6 records

Segments3 records

Ideal customer profiles2 records

Technology focussed Yes

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

AI capability5 records

Feature5 records

Partnerships

Eleven partnerships are on record, tiered core and minor.

• Karolinska InstitutetcoreStrategic or Co-development PartnerKarolinska Institutet is a key academic partner. The company's digital tools are developed in collaboration with healthcare providers and have been clinically validated at Karolinska University Hospital. Karolinska Innovation has featured the partnership.
• Karolinska UniversitetssjukhusetcoreStrategic or Co-development PartnerClinical validation partner where the methodology was clinically tested. Neuropsychologist Göran Hagman serves as a key reference and advisory board member.
• Svenskt DemenscentrumcoreStrategic or Co-development PartnerGeriatric specialist Wilhelmina Hoffman, head of Svenskt Demenscentrum, provides expert endorsements and validation of the digital tools.
• Region VärmlandcoreStrategic or Co-development PartnerRegional healthcare authority partnership for deployment of digital dementia assessment services across the region.
• Region HallandcoreStrategic or Co-development PartnerRegional healthcare authority partnership for deployment of digital dementia assessment services.
• Region Västra GötalandcoreStrategic or Co-development PartnerRegional healthcare authority partnership for deployment of digital dementia assessment services.
• Region SörmlandcoreStrategic or Co-development PartnerRegional healthcare authority partnership for deployment of digital dementia assessment services.
• AlzheimerfondenminorGTM or Marketing PartnerCharitable foundation partner supporting dementia research and awareness. Listed as partner on the website.
• DemensförbundetminorGTM or Marketing PartnerSwedish Dementia Association partnership for patient advocacy and awareness.
• Alzheimer SverigeminorGTM or Marketing PartnerSwedish Alzheimer's Association partnership for patient advocacy.
• Swedish Institute for Health Economics (IHE)minorStrategic or Co-development PartnerHealthcare economics research partnership.

Scale indicators1 record

Recent moves6 records

Expansion highlights4 records

Direct peers

• Linus Health: Boston-based digital cognitive assessment platform offering tablet-based tests and clinical decision support for healthcare providers. Directly comparable to Geras's Geras Suite in product, customer segment (primary care and memory clinics), and core use case (early dementia/MCI detection).
• Cambridge Cognition: UK-based provider of CANTAB digital cognitive testing solutions for clinical trials, research, and healthcare. Closely comparable to Geras's pharma/research offering with validated digital endpoints and overlaps in MoCA/MMSE-adjacent screening.
• Cogstate: Australia/US-listed digital cognitive assessment company specializing in computerized tests for clinical trials across CNS indications. Same product category, same primary customer (pharma), and overlapping use of cognitive endpoints in trials.
• BrainCheck: Houston-based digital cognitive testing and concussion/memory screening platform sold to clinicians and health systems. Directly competes in digital cognitive testing for primary care with similar tablet-based delivery.
• Altoida: Swiss/US digital biomarker company using smartphone/tablet AR-based tasks for early Alzheimer's prediction. Comparable AI-driven, device-based cognitive assessment product targeting pharma and clinical customers.
• Cognivue: US FDA-cleared computerized cognitive assessment device used in primary care for early dementia detection. Direct competitor in regulated, device-based cognitive screening with similar clinical validation strategy.
• Neurotrack: US digital cognitive health company offering online memory assessments and brain-health programs. Comparable in the patient-facing risk-reduction/memory assessment category to Geras's Minnesmottagningen and FINGER-based app.

Emerging players

• Cumulus Neuroscience: UK-based CNS assessment platform combining digital cognitive testing with EEG biomarkers for clinical trial endpoints. Partial overlap with Geras Solutions for Pharma & Akademi in validated digital cognitive endpoints.

Broad incumbents

• Biogen: Large biotech with deep investment in Alzheimer's therapeutics and a growing program of digital biomarker partnerships. Represents the strategic buyer side of the market in which Geras competes for digital endpoint contracts.
• Roche: Global diagnostics and pharma incumbent with companion-diagnostic and digital-health initiatives for dementia. Comparable as a potential partner or competitor in scalable cognitive assessment and as the typical enterprise buyer for CNS trials.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat4 records

Key risks5 records

Key highlights7 records

Customer concentration

• Xx.com/geras_solutions

Compliance2 records

Revenue estimate

Valuation estimate

Number of profiles

Profiles20 records

Funding overview

Funding rounds1 record

Investors1 record

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Geras Solutions